

Oligomannose Glycoforms
M5
M6
M7
ABT-874 Glycoform Concentration (µg/mL)
1000
100
10
1
0.1
0.01
0
2
4
6
8
10
12
14
Time (Day)

Fig. 1A



FBO Glycoforms
ABT-874 Glycoform Concentration (µg/mL)
1000
100
10
1
0.1
0.01
0
2
4
6
8
10
12
14
Time (Day)
NA2F
NAF1 GlcNac
NAF1 Total
NGA2F
NGA2F GlcNac

Fig. 1B



Group 1 Glycoforms
Group 2 Glycoforms
ABT874 Glycoform Concentration (µg/mL)
0
100
200
300
400
500
Time (Days)
0
2
4
6
8
10
12
14

Fig. 2A



Group 1 Glycoforms
Group 2 Glycoforms
ABT874 Glycoform Concentration (µg/mL)
1000
100
10
1
0.1
0.01
0
2
4
6
8
10
12
14
Time (Days)

Fig. 2B



Predicted Conc. (IPRE)
Observed Conc. (mcg/mL)
Conditional Weighted Residuals
Predicted Concentration (PRED)

Fig. 3





Fig. 3 (Continued)


1000.0
100.0
10.0
1.0
0.1
Concentration (mcg/mL)
0
10
20
30
Time (days)



100.0
10.0
1.0
0.1
Concentration (mcg/mL)
0
10
20
30
Time (days)

Fig. 4




PK profile of pure FBO and Oligomannose
Median and 90% prediction interval
FBO
Oligomannose
Concentration (mcg/mL)
1000
100
10
1
0.1
0
5
10
15
20
25
Time (days)

Fig. 5


PK profile of 90/10 and 60/40 combination
Median and 90% prediction interval
90/10
60/40
Concentration (mcg/mL)
1000
100
10
1
0.1
0
5
10
15
20
25
Time (days)



PK profile of 90/10 and 60/40 combination
Median and 90% prediction interval
90/10
60/40
Concentration (mcg/mL)
1000
100
10
1
0.1
0
5
10
15
20
25
Time (days)

Fig. 6



AUC 100/0
N= 75 per Arm
AUC 95/5
N= 75 per Arm
AUC 90/10
N= 75 per Arm
AUC 60/20
N= 75 per Arm
AUC 70/30
N= 75 per Arm
AUC 60/40
N= 75 per Arm
Replicate (ordered by lower limit)
0
200
400
600
800
1000
0.8
1.0
1.2
1.4
Ratio to 90/10

Fig. 7





C_{max} 100/0
N= 75 per Arm
C_{max} 95/5
N= 75 per Arm
C_{max} 90/10
N= 75 per Arm
C_{max} 60/20
N= 75 per Arm
C_{max} 70/30
N= 75 per Arm
C_{max} 60/40
N= 75 per Arm
Replicate (ordered by lower limit)
0
200
400
600
800
1000
0.8
1.0
1.2
1.4
Ratio to 90/10

Fig. 8


Percent of failed simulated studies
(AUC with N=75/arm)
Percent
25
20
15
10
5
0
100/0
95/5
90/10
80/20
70/30
60/40
Glycoforms


Percent of failed simulated studies
(C_{max} with N=75/arm)
Percent
25
20
15
10
5
0
100/0
95/5
90/10
80/20
70/30
60/40
Glycoforms



Percent of failed simulated studies
(C_{max} or AUC with N=75/arm)
Percent
25
20
15
10
5
0
100/0
95/5
90/10
80/20
70/30
60/40
Glycoforms

Fig. 9